Literature DB >> 10773186

Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials.

D O Perkins1, R J Wyatt, J J Bartko.   

Abstract

BACKGROUND: Clinical research studies must compensate for measurement error by increasing the number of subjects that are studied, thereby increasing the financial costs of research and exposing greater numbers of subjects to study risks. In this article, we model the relationship between reliability and sample-size requirements and consider the potential tangible cost savings resulting from the decreased number of subjects needed when reliability of raters is improved or multiple ratings are used.
METHODS: Standard methods are used to model reliability based on the intraclass correlation coefficient (R) and to perform power calculations. The impact of multiple raters on reliability for a given baseline level of reliability is modeled according to the Spearman Brown formula.
RESULTS: Our models demonstrate that meaningful reductions in sample size requirements are gained from improvements in reliability. For example, improving reliability from R = .7 to R = .9 will decreases sample size requirements by 22%. Reliability is improved by training and by the use of the mean of multiple ratings. For example, if the reliability of a single rating is 0.7, the reliability of the mean of two ratings will be 0.8.
CONCLUSIONS: The costs to improve reliability either through rater training efforts or use of the mean of multiple ratings is cost effective because of the consequent reduction in number of subjects needed. Efforts to improve reliability and thus reduce subject requirements in a study also may lead to fewer patients bearing the burden of research participation and to a shortening of the duration of studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773186     DOI: 10.1016/s0006-3223(00)00837-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  31 in total

1.  What sample sizes for reliability and validity studies in neurology?

Authors:  Jeremy C Hobart; Stefan J Cano; Thomas T Warner; Alan J Thompson
Journal:  J Neurol       Date:  2012-06-24       Impact factor: 4.849

2.  Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa.

Authors:  J S Kirby; M Butt; T King
Journal:  Br J Dermatol       Date:  2019-08-27       Impact factor: 9.302

Review 3.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

Review 4.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 5.  Do antidepressants really work? A clinicians' guide to evaluating the evidence.

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

6.  Test-retest reliability of amygdala response to emotional faces.

Authors:  Colin L Sauder; Greg Hajcak; Mike Angstadt; K Luan Phan
Journal:  Psychophysiology       Date:  2013-10-16       Impact factor: 4.016

7.  The reliability of end of day and ecological momentary assessments of pain and pain interference in individuals with spinal cord injury.

Authors:  Noelle E Carlozzi; Stephen Schilling; Jenna Freedman; Claire Z Kalpakjian; Anna L Kratz
Journal:  Qual Life Res       Date:  2018-08-02       Impact factor: 4.147

Review 8.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

10.  Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Authors:  Shaunna L Clark; Renan P Souza; Daniel E Adkins; Karolina Aberg; József Bukszár; Joseph L McClay; Patrick F Sullivan; Edwin J C G van den Oord
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.